Eris Lifesciences Limited — Board Meeting, 24-11-2025: Outcome of Board Meeting

Eris Lifesciences board approved acquiring the remaining 30% of Swiss Parenterals for ₹423.30 Cr via a share swap. This makes Swiss a wholly-owned subsidiary, boosting operational synergy. Eris will issue 23.06 lakh shares at ₹1,835.35 to fund the deal. Shareholders will vote via postal ballot.